Dehydroepiandrosterone (DHEA), Four Specimens
Use
The Dehydroepiandrosterone (DHEA) Four Specimens test is used to evaluate adrenal gland function and endocrine disorders related to DHEA production. This series panel involves collecting an initial baseline sample, followed by administering a treatment to the patient, and subsequently collecting additional samples at different time points to assess changes in DHEA levels. It aids in diagnosing conditions such as adrenal hyperplasia and adrenal tumors.
Special Instructions
This test requires multiple specimen collections at different time points following treatment administration. Refer to the Endocrine Appendix of the LabCorp Directory of Services for detailed instructions on the collection process. Ensure that the ordering clinician is contacted to confirm the necessity of this series test before collection if the treatment is not administered. This panel should not be used if a treatment is not administered after the initial sample draw.
Limitations
This test has not been cleared or approved by the FDA, and the performance characteristics were determined by LabCorp. The results may be affected by medication, medical conditions, and timing of the sample collection. Confirmatory or additional reflex tests may be needed to validate results or provide more comprehensive insights.
Methodology
Automated Analyzer (Clinical Chemistry)
Biomarkers
LOINC Codes
- 12590-6
- 12591-4
- 12592-2
- 2193-1
- 46963-5
- 2193-1
- 46963-5
- 12590-6
- 12591-4
- 12592-2
Result Turnaround Time
4-6 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
This panel involves collecting an initial tube followed by additional tubes at multiple time points after treatment administration. Ensure proper labeling and sequence as Tube ID #1, #2, #3, and #4.
Causes for Rejection
Incorrect labeling, improper collection sequence, or missing samples